Gsk (GSK) Receivables Refunds (2009 - 2026)

Gsk's Receivables Refunds history runs 18 years deep, the most recent figure standing at $244.0 million for Q1 2026.

• In Q1 2026, Receivables Refunds fell 56.17% year-over-year to $244.0 million; the TTM figure through Mar 2026 stood at $244.0 million (down 56.17% YoY), while the FY2025 annual figure was $379.7 million, down 39.25% from the prior year.
• Receivables Refunds was $244.0 million for Q1 2026 at Gsk, down from $383.1 million in the prior quarter.
• In the past five years, Receivables Refunds ranged from a high of $690.6 million in Q3 2022 to a low of $222.7 million in Q1 2022.
• Historically, Receivables Refunds has averaged $483.8 million across 5 years, with a median of $495.2 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Receivables Refunds tumbled 76.62% in 2022, then jumped 64.11% in 2024.
• A 5-year view of Receivables Refunds shows it stood at $475.0 million in 2022, then fell by 2.54% to $462.9 million in 2023, then soared by 35.57% to $627.6 million in 2024, then sank by 38.96% to $383.1 million in 2025, then plunged by 36.3% to $244.0 million in 2026.
• The last three Receivables Refunds figures came in at $244.0 million (Q1 2026), $383.1 million (Q4 2025), and $495.2 million (Q3 2025), per Business Quant data.